已收录 273175 条政策
 政策提纲
  • 暂无提纲
Onco-Nephrology: Tumor Lysis Syndrome
[摘要] Tumor lysis syndrome (TLS) describes the clinical and laboratory sequelae that result from the rapid release of intracellular contents of dying cancer cells. It is characterized by the release of potassium, phosphorous, and nucleic acids from cancer cells into the blood stream, with the potential to cause hyperkalemia; hyperphosphatemia and secondary hypocalcemia; hyperuricemia; AKI; and, should usual homeostatic mechanisms fail, death. TLS most commonly follows treatment of hematologic malignancies, such as acute lymphocytic or lymphoblastic leukemia, acute myeloid leukemia, and Burkitt lymphoma, but also occurs after treatment of other bulky or rapidly growing tumors, particularly if the patient is highly sensitive to the effects of cytotoxic chemotherapy. Prevention and treatment depend on prompt recognition of patients at risk, volume repletion, allopurinol, rasburicase (a novel recombinant urate oxidase), and, when indicated, dialysis.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 泌尿医学
[关键词] Bone marrow necrosis;Sickle cell disease;Hyperhemolysis syndrome [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文